- TRXC +78% FDA's 510(k) clearance for its Senhance System.
- RCON +26% on signing a three-year strategic cooperation agreement with Beijing OriginWater Purification Engineering Technology.
- LBIX +27%.
- RT +20% on Q2 result.
- EXEL +16% on Cabometyx successful in late-stage liver cancer study.
- HIIQ +14% on preliminary Q3 results.
- VHC +13% on court document release.
- XXII +10%.
- OTCPK:HMNY +10%.
- CARA +9% on successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration.
- RWLK +8% as it begins next phase of testing in pre-clinical study.
- NETE +8% on launching Same-Day ACH payment processing solutions.
- AEMD +8% on collaboration with iBio (IBIO).
- ABEO +7% on receiving grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programs.
- PZRX +7% on analyst action.
- ONCS +7%.
- CLSN +7%.
- AU +6%.
- ETRM +6%.
- MNKD +5%.